Mauna Kea Technologies
The Princess Grace Hospital Centre Chooses French Imaging System to Improve Cancer Detection Techniques and Speed Treatment

Mauna Kea Technologies / 

08.10.2009 

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PARIS, Oct. 8, 2009 (GLOBE NEWSWIRE) -- The Princess Grace Hospital Centre in
Monaco has installed the world's smallest and most flexible imaging system
capable of observing living, internal tissues at a microscopic level. The
technology, known as Cellvizio, helps physicians accurately pinpoint diseased
tissue inside the body in real time and remove it on the spot or determine a
proper treatment. 

The GEMLUC (Groupement des Entreprises Monegasques dans la Lutte contre le
cancer) group of companies in the Monaco region provided a grant for the
system, as part of the organization's commitment to fight cancer. 

Developed in Paris, France, by Mauna Kea Technologies, the Cellvizio system is
used with regular endoscopic tools during colonoscopies, upper endoscopies and
diagnostic procedures within the bile or pancreatic ducts to detect cancer or
disease more effectively and efficiently. Clinical trials focusing on the
biliary duct, for example, have proven that Cellvizio increases the detection
rate of unknown cancers by as much as 50%. 

'We are very proud that The Princess Grace Hospital Centre has chosen Cellvizio
to provide physicians with a unique in vivo imaging tool that improves
diagnostic performance while reducing the need for additional procedures and
the long waits for biopsy results,' said Sacha Loiseau, President, CEO and
Founder of Mauna Kea Technologies, speaking after the inauguration ceremony
attended by Her Royal Highness the Princess Caroline of Hanover. 'This
technology has been a major priority for hospitals as they realize the tangible
benefits of early disease and cancer detection.' 

Physicians and thought leaders at almost one hundred top medical institutions
around the world have completed over 3,000 procedures with Cellvizio and have
published more than 25 peer-reviewed papers on the technology in major medical
journals. Cellvizio has 510(k) clearance from the U.S. Food and Drug
Administration and the European CE-Mark for use in the gastrointestinal and
pulmonary tracts. 

About Mauna Kea Technologies

Mauna Kea Technologies is a medical device company based in Paris, France. With
its flagship Cellvizio system, the company leads the growing in vivo cellular
imaging market, enabling physicians to visualize, diagnose and treat
pathologies that cannot be seen using other imaging techniques. Investors
include Psilos Group, Seventure and Creadev. For more information about Mauna
Kea Technologies visit www.maunakeatech.com. 

CONTACT: Mauna Kea Technologies
         Media Contact:
         Ken Purcell
         +331 7008 0976
         ken@maunakeatech.com

News Source: NASDAQ OMX



08.10.2009  Financial News transmitted by DGAP

---------------------------------------------------------------------------
 
Language:     English
Company:      Mauna Kea Technologies
              
               
              United States
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         US9901025844
WKN:          
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------